医療用食品市場(製品タイプ:錠剤、粉末、液体、その他、投与経路:経口、経腸)-世界の産業分析、サイズ、シェア、成長、トレンド、予測、2023-2031年Medical Foods Market (Product Type: Pills, Powder, Liquid, and Others; Route of Administration: Oral and Enteral) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031 医療用食品市場 - レポートの範囲 TMRの調査レポート「世界の医療用食品市場」は、2023年から2031年までの予測期間における市場の指標について貴重な洞察を得るために、過去だけでなく現在の成長動向や機会も調... もっと見る
サマリー医療用食品市場 - レポートの範囲TMRの調査レポート「世界の医療用食品市場」は、2023年から2031年までの予測期間における市場の指標について貴重な洞察を得るために、過去だけでなく現在の成長動向や機会も調査しています。本レポートでは、2023年を基準年、2031年を予測年として考え、2017年から2031年までの期間における世界の医療用食品市場の収益を提供します。また、2023年から2031年までの世界の医療用食品市場の複合年間成長率(CAGR %)を掲載しています。 本レポートは、広範な調査を経て作成されました。一次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施し、調査作業の大部分を行った。二次調査では、医療用食品市場を理解するために、主要企業の製品資料、年次報告書、プレスリリース、および関連文書を参照した。 二次調査には、インターネットソース、政府機関の統計データ、ウェブサイト、業界団体も含まれます。アナリストは、トップダウンアプローチとボトムアップアプローチを組み合わせて、世界の医療用食品市場のさまざまな属性を調査しました。 本レポートには、調査範囲に含まれるさまざまなセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、本レポートは、世界の医療用食品市場における競争力学の変化に光を当てています。これらは、既存の市場関係者だけでなく、世界の医療用食品市場への参入に関心を持つ企業にとっても貴重なツールとなります。 本レポートは、世界の医療用食品市場の競争環境について掘り下げています。世界の医療用食品市場で事業を展開する主要企業が特定され、それぞれの企業がさまざまな属性でプロファイリングされています。会社概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界の医療用食品市場のプレーヤーの属性です。 医療用食品の世界市場レポートで回答された主要な質問 - 予測期間中の全地域における医療用食品の売上高/収益はどの程度か? - 世界の医療用食品市場におけるビジネスチャンスは何か? - 市場における主な推進要因、阻害要因、機会、脅威は何か? - 予測期間中に最も速いCAGRで拡大するのはどの地域市場か? - 2031年に世界で最も高い収益を上げると予測されるセグメントは? - 予測期間中に最も高いCAGRで拡大すると予測されるセグメントはどこか? - 世界市場で事業を展開する各企業の市場ポジションはどのようなものか? 医療用食品市場 - 研究目的と研究アプローチ 医療用食品の世界市場に関する包括的なレポートは、まず概要から始まり、次に調査範囲と目的について説明しています。本調査の目的、市場で活動する主要ベンダーや流通業者、製品の承認に関する規制シナリオについて詳しく解説しています。 読みやすさを考慮し、本レポートは章立てでまとめられ、各セクションはより小さなものに分割されています。本レポートは、グラフと表が適切に配置された包括的なコレクションで構成されています。主要セグメントの実績値と予測値を図式化し、読者に視覚的に訴えかけています。また、過去と予測期間終了時の主要セグメントの市場シェアを比較することも可能です。 本レポートでは、世界の医療用食品市場を製品、エンドユーザー、地域の観点から分析しています。各基準の主要セグメントを詳細に調査し、2031年末時点の各セグメントごとの市場シェアを掲載しています。このような貴重な洞察により、市場関係者は世界の医療用食品市場への投資について、情報に基づいたビジネス上の意思決定を行うことができます。 目次1. Preface1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global Medical Foods Market 4. Market Overview 4.1. Introduction 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 5. Key Insights 5.1. Important market developments 5.2. Top 3 Players Operating in the Market Space 5.3. New competitive market entrants 5.4. Medical food regulation overview 5.5. Reimbursement Scenario 5.6. Overview of the Distribution Channel of Medical Foods in various diseases along with examples 6. Global Medical Foods Market Analysis and Forecast, by Product Type 6.1. Introduction & Definition 6.2. Key Findings / Developments 6.3. Market Value Forecast, by Product Type, 2017–2031 6.3.1. Pills 6.3.2. Powder 6.3.3. Liquid 6.3.4. Others 6.4. Market Attractiveness Analysis, by Product Type 7. Global Medical Foods Market Analysis and Forecast, by Disease Type 7.1. Introduction & Definition 7.2. Key Findings / Developments 7.3. Market Value Forecast, by Disease Type, 2017–2031 7.3.1. Orphan Disease 7.3.1.1. Duchenne Muscular Dystrophy (DMD) 7.3.1.2. Sickle Cell Anemia 7.3.1.3. Hemophilia 7.3.1.4. Others 7.3.2. Cancer 7.3.3. Neurological & Psychological Disorders 7.3.4. Metabolic Disorders 7.3.5. Pain Management 7.3.6. Gastrointestinal Disorders 7.3.7. Ophthalmology 7.3.8. Diabetes 7.3.9. Phenylketonuria (PKU) 7.3.10. Epilepsy 7.4. Market Attractiveness Analysis, by Disease Type 8. Global Medical Foods Market Analysis and Forecast, by Route of Administration 8.1. Introduction & Definition 8.2. Key Findings / Developments 8.3. Market Value Forecast, by Route of Administration, 2017–2031 8.3.1. Oral 8.3.2. Enteral 8.4. Market Attractiveness Analysis, by Route of Administration 9. Global Medical Foods Market Analysis and Forecast, by Distribution Channel 9.1. Introduction & Definition 9.2. Key Findings / Developments 9.3. Market Value Forecast, by Distribution Channel, 2017–2031 9.3.1. Pharmacies & Drug Stores 9.3.2. Online Channels 9.3.3. Supermarkets & Hypermarkets 9.3.4. Others 9.4. Market Attractiveness Analysis, by Distribution Channel 10. Global Medical Foods Market Analysis and Forecast, by Region 10.1. Key Findings 10.2. Market Value Forecast, by Region 10.2.1. North America 10.2.2. Europe 10.2.3. Asia Pacific 10.2.4. Latin America 10.2.5. Middle East & Africa 10.3. Market Attractiveness Analysis, by Region 11. North America Medical Foods Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Market Value Forecast, by Product Type, 2017–2031 11.2.1. Pills 11.2.2. Powder 11.2.3. Liquid 11.2.4. Others 11.3. Market Value Forecast, by Disease Type, 2017–2031 11.3.1. Orphan Disease 11.3.1.1. Duchenne Muscular Dystrophy (DMD) 11.3.1.2. Sickle Cell Anemia 11.3.1.3. Hemophilia 11.3.1.4. Others 11.3.2. Cancer 11.3.3. Neurological & Psychological Disorders 11.3.4. Metabolic Disorders 11.3.5. Pain Management 11.3.6. Gastrointestinal Disorders 11.3.7. Ophthalmology 11.3.8. Diabetes 11.3.9. Phenylketonuria (PKU) 11.3.10. Epilepsy 11.4. Market Value Forecast, by Route of Administration, 2017–2031 11.4.1. Oral 11.4.2. Enteral 11.5. Market Value Forecast, by Distribution Channel, 2017–2031 11.5.1. Pharmacies & Drug Stores 11.5.2. Online Channels 11.5.3. Supermarkets & Hypermarkets 11.5.4. Others 11.6. Market Value Forecast, by Country, 2017–2031 11.6.1. U.S. 11.6.2. Canada 11.7. Market Attractiveness Analysis 11.7.1. By Product 11.7.2. By Disease Type 11.7.3. By Route of Administration 11.7.4. By Distribution Channel 11.7.5. By Country 12. Europe Medical Foods Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.2. Market Value Forecast, by Product Type, 2017–2031 12.2.1. Pills 12.2.2. Powder 12.2.3. Liquid 12.2.4. Others 12.3. Market Value Forecast, by Disease Type, 2017–2031 12.3.1. Orphan Disease 12.3.1.1. Duchenne Muscular Dystrophy (DMD) 12.3.1.2. Sickle Cell Anemia 12.3.1.3. Hemophilia 12.3.1.4. Others 12.3.2. Cancer 12.3.3. Neurological & Psychological Disorders 12.3.4. Metabolic Disorders 12.3.5. Pain Management 12.3.6. Gastrointestinal Disorders 12.3.7. Ophthalmology 12.3.8. Diabetes 12.3.9. Phenylketonuria (PKU) 12.3.10. Epilepsy 12.4. Market Value Forecast, by Route of Administration, 2017–2031 12.4.1. Oral 12.4.2. Enteral 12.5. Market Value Forecast, by Distribution Channel, 2017–2031 12.5.1. Pharmacies & Drug Stores 12.5.2. Online Channels 12.5.3. Supermarkets & Hypermarkets 12.5.4. Others 12.6. Market Value Forecast, by Country/Sub-region, 2017–2031 12.6.1. Germany 12.6.2. U.K. 12.6.3. France 12.6.4. Spain 12.6.5. Italy 12.6.6. Rest of Europe 12.7. Market Attractiveness Analysis 12.7.1. by Product Type 12.7.2. By Disease Type 12.7.3. By Route of Administration 12.7.4. By Distribution Channel 12.7.5. By Country/Sub-region 13. Asia Pacific Medical Foods Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.2. Market Value Forecast, by Product Type, 2017–2031 13.2.1. Pills 13.2.2. Powder 13.2.3. Liquid 13.2.4. Others 13.3. Market Value Forecast, by Disease Type, 2017–2031 13.3.1. Orphan Disease 13.3.1.1. Duchenne Muscular Dystrophy (DMD) 13.3.1.2. Sickle Cell Anemia 13.3.1.3. Hemophilia 13.3.1.4. Others 13.3.2. Cancer 13.3.3. Neurological & Psychological Disorders 13.3.4. Metabolic Disorders 13.3.5. Pain Management 13.3.6. Gastrointestinal Disorders 13.3.7. Ophthalmology 13.3.8. Diabetes 13.3.9. Phenylketonuria (PKU) 13.3.10. Epilepsy 13.4. Market Value Forecast, by Route of Administration, 2017–2031 13.4.1. Oral 13.4.2. Enteral 13.5. Market Value Forecast, by Distribution Channel, 2017–2031 13.5.1. Pharmacies & Drug Stores 13.5.2. Online Channels 13.5.3. Supermarkets & Hypermarkets 13.5.4. Others 13.6. Market Value Forecast, by Country/Sub-region, 2017–2031 13.6.1. China 13.6.2. Japan 13.6.3. India 13.6.4. Australia & New Zealand 13.6.5. Rest of Asia Pacific 13.7. Market Attractiveness Analysis 13.7.1. by Product Type 13.7.2. By Disease Type 13.7.3. By Route of Administration 13.7.4. By Distribution Channel 13.7.5. By Country/Sub-region 14. Latin America Medical Foods Market Analysis and Forecast 14.1. Introduction 14.1.1. Key Findings 14.2. Market Value Forecast, by Product Type, 2017–2031 14.2.1. Pills 14.2.2. Powder 14.2.3. Liquid 14.2.4. Others 14.3. Market Value Forecast, by Disease Type, 2017–2031 14.3.1. Orphan Disease 14.3.1.1. Duchenne Muscular Dystrophy (DMD) 14.3.1.2. Sickle Cell Anemia 14.3.1.3. Hemophilia 14.3.1.4. Others 14.3.2. Cancer 14.3.3. Neurological & Psychological Disorders 14.3.4. Metabolic Disorders 14.3.5. Pain Management 14.3.6. Gastrointestinal Disorders 14.3.7. Ophthalmology 14.3.8. Diabetes 14.3.9. Phenylketonuria (PKU) 14.3.10. Epilepsy 14.4. Market Value Forecast, by Route of Administration, 2017–2031 14.4.1. Oral 14.4.2. Enteral 14.5. Market Value Forecast, by Distribution Channel, 2017–2031 14.5.1. Pharmacies & Drug Stores 14.5.2. Online Channels 14.5.3. Supermarkets & Hypermarkets 14.5.4. Others 14.6. Market Value Forecast, by Country/Sub-region, 2017–2031 14.6.1. Brazil 14.6.2. Mexico 14.6.3. Rest of Latin America 14.7. Market Attractiveness Analysis 14.7.1. by Product Type 14.7.2. By Disease Type 14.7.3. By Route of Administration 14.7.4. By Distribution Channel 14.7.5. By Country/Sub-region 15. Middle East & Africa Medical Foods Market Analysis and Forecast 15.1. Introduction 15.1.1. Key Findings 15.2. Market Value Forecast, by Product Type, 2017–2031 15.2.1. Pills 15.2.2. Powder 15.2.3. Liquid 15.2.4. Others 15.3. Market Value Forecast, by Disease Type, 2017–2031 15.3.1. Orphan Disease 15.3.1.1. Duchenne Muscular Dystrophy (DMD) 15.3.1.2. Sickle Cell Anemia 15.3.1.3. Hemophilia 15.3.1.4. Others 15.3.2. Cancer 15.3.3. Neurological & Psychological Disorders 15.3.4. Metabolic Disorders 15.3.5. Pain Management 15.3.6. Gastrointestinal Disorders 15.3.7. Ophthalmology 15.3.8. Diabetes 15.3.9. Phenylketonuria (PKU) 15.3.10. Epilepsy 15.4. Market Value Forecast, by Route of Administration, 2017–2031 15.4.1. Oral 15.4.2. Enteral 15.5. Market Value Forecast, by Distribution Channel, 2017–2031 15.5.1. Pharmacies & Drug Stores 15.5.2. Online Channels 15.5.3. Supermarkets & Hypermarkets 15.5.4. Others 15.6. Market Value Forecast, by Country/Sub-region, 2017–2031 15.6.1. GCC Countries 15.6.2. South Africa 15.6.3. Rest of Middle East & Africa 15.7. Market Attractiveness Analysis 15.7.1. by Product Type 15.7.2. By Disease Type 15.7.3. By Route of Administration 15.7.4. By Distribution Channel 15.7.5. By Country/Sub-region 16. Competition Landscape 16.1. Market Player - Competition Matrix (by tier and size of companies) 16.2. Competitive Business Strategies 16.3. Company Profiles 16.3.1. Nutricia (Danone) 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.1.2. Product Portfolio 16.3.1.3. Financial Overview 16.3.1.4. SWOT Analysis 16.3.1.5. Strategic Overview 16.3.2. Nestlé S.A. 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.2.2. Product Portfolio 16.3.2.3. Financial Overview 16.3.2.4. SWOT Analysis 16.3.2.5. Strategic Overview 16.3.3. Abbott Laboratories 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.3.2. Product Portfolio 16.3.3.3. Financial Overview 16.3.3.4. SWOT Analysis 16.3.3.5. Strategic Overview 16.3.4. Mead Johnson Nutrition 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.4.2. Product Portfolio 16.3.4.3. Financial Overview 16.3.4.4. SWOT Analysis 16.3.4.5. Strategic Overview 16.3.5. Fresenius Kabi 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.5.2. Product Portfolio 16.3.5.3. Financial Overview 16.3.5.4. SWOT Analysis 16.3.5.5. Strategic Overview 16.3.6. Friso 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.6.2. Product Portfolio 16.3.6.3. Financial Overview 16.3.6.4. SWOT Analysis 16.3.6.5. Strategic Overview 16.3.7. Morinaga Milk Industry 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.7.2. Product Portfolio 16.3.7.3. Financial Overview 16.3.7.4. SWOT Analysis 16.3.7.5. Strategic Overview 16.3.8. Primus Pharmaceuticals, Inc. 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.8.2. Product Portfolio 16.3.8.3. Financial Overview 16.3.8.4. SWOT Analysis 16.3.8.5. Strategic Overview 16.3.9. Targeted Medical Pharma, Inc. 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.9.2. Product Portfolio 16.3.9.3. Financial Overview 16.3.9.4. SWOT Analysis 16.3.9.5. Strategic Overview 16.3.10. Medtrition, Inc. 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.10.2. Product Portfolio 16.3.10.3. Financial Overview 16.3.10.4. SWOT Analysis 16.3.10.5. Strategic Overview 図表リストList of TablesTable 01: Global Medical Foods Market Value (US$ Mn) Forecast, by Product Type, 2017–2031 Table 02: Global Medical Foods Market Value (US$ Mn) Forecast, by Disease Type, 2017–2031 Table 03: Global Medical Foods Market Value (US$ Mn) Forecast, by Orphan Disease, 2017–2031 Table 04: Global Medical Foods Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031 Table 05: Global Medical Foods Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 06: Global Medical Foods Market Value (US$ Mn) Forecast, by Country, 2017–2031 Table 07: Europe Medical Foods Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031 Table 08: Europe Medical Foods Market Value (US$ Mn) Forecast, by Product Type, 2017–2031 Table 09: Europe Medical Foods Market Value (US$ Mn) Forecast, by Disease Type, 2017‒2031 Table 10: Europe Medical Foods Market Value (US$ Mn) Forecast, by Orphan Disease, 2017‒2031 Table 11: Europe Medical Foods Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031 Table 12: Europe Medical Foods Value (US$ Mn) Forecast, by Distribution Channel, 2017‒2031 Table 13: North America Medical Foods Market Value (US$ Mn) Forecast, by Product Type, 2017–2031 Table 14: North America Medical Foods Market Value (US$ Mn) Forecast, by Disease Type, 2017‒2031 Table 15: North America Medical Foods Market Value (US$ Mn) Forecast, by Orphan Disease, 2017‒2031 Table 16: North America Medical Foods Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031 Table 17: North America Medical Foods Value (US$ Mn) Forecast, by Distribution Channel, 2017‒2031 Table 18: Asia Pacific Medical Foods Market Value (US$ Mn) Forecast, by Product Type, 2017–2031 Table 19: Asia Pacific Medical Foods Market Value (US$ Mn) Forecast, by Disease Type, 2017‒2031 Table 20: Asia Pacific Medical Foods Market Value (US$ Mn) Forecast, by Orphan Disease, 2017‒2031 Table 21: Asia Pacific Medical Foods Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031 Table 22: Asia Pacific Medical Foods Value (US$ Mn) Forecast, by Distribution Channel, 2017‒2031 Table 23: Latin America Medical Foods Market Value (US$ Mn) Forecast, by Product Type, 2017–2031 Table 24: Latin America Medical Foods Market Value (US$ Mn) Forecast, by Disease Type, 2017‒2031 Table 25: Latin America Medical Foods Market Value (US$ Mn) Forecast, by Orphan Disease, 2017‒2031 Table 26: Latin America Medical Foods Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031 Table 27: Latin America Medical Foods Value (US$ Mn) Forecast, by Distribution Channel, 2017‒2031 Table 28: Middle East and Africa Medical Foods Market Value (US$ Mn) Forecast, by Product Type, 2017–2031 Table 29: Middle East and Africa Medical Foods Market Value (US$ Mn) Forecast, by Disease Type, 2017‒2031 Table 30: Middle East and Africa Medical Foods Market Value (US$ Mn) Forecast, by Orphan Disease, 2017‒2031 Table 31: Middle East and Africa Medical Foods Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031 Table 32: Middle East and Africa Medical Foods Value (US$ Mn) Forecast, by Distribution Channel, 2017‒2031
SummaryMedical Foods Market – Scope of Report Table of Contents1. Preface1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global Medical Foods Market 4. Market Overview 4.1. Introduction 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 5. Key Insights 5.1. Important market developments 5.2. Top 3 Players Operating in the Market Space 5.3. New competitive market entrants 5.4. Medical food regulation overview 5.5. Reimbursement Scenario 5.6. Overview of the Distribution Channel of Medical Foods in various diseases along with examples 6. Global Medical Foods Market Analysis and Forecast, by Product Type 6.1. Introduction & Definition 6.2. Key Findings / Developments 6.3. Market Value Forecast, by Product Type, 2017–2031 6.3.1. Pills 6.3.2. Powder 6.3.3. Liquid 6.3.4. Others 6.4. Market Attractiveness Analysis, by Product Type 7. Global Medical Foods Market Analysis and Forecast, by Disease Type 7.1. Introduction & Definition 7.2. Key Findings / Developments 7.3. Market Value Forecast, by Disease Type, 2017–2031 7.3.1. Orphan Disease 7.3.1.1. Duchenne Muscular Dystrophy (DMD) 7.3.1.2. Sickle Cell Anemia 7.3.1.3. Hemophilia 7.3.1.4. Others 7.3.2. Cancer 7.3.3. Neurological & Psychological Disorders 7.3.4. Metabolic Disorders 7.3.5. Pain Management 7.3.6. Gastrointestinal Disorders 7.3.7. Ophthalmology 7.3.8. Diabetes 7.3.9. Phenylketonuria (PKU) 7.3.10. Epilepsy 7.4. Market Attractiveness Analysis, by Disease Type 8. Global Medical Foods Market Analysis and Forecast, by Route of Administration 8.1. Introduction & Definition 8.2. Key Findings / Developments 8.3. Market Value Forecast, by Route of Administration, 2017–2031 8.3.1. Oral 8.3.2. Enteral 8.4. Market Attractiveness Analysis, by Route of Administration 9. Global Medical Foods Market Analysis and Forecast, by Distribution Channel 9.1. Introduction & Definition 9.2. Key Findings / Developments 9.3. Market Value Forecast, by Distribution Channel, 2017–2031 9.3.1. Pharmacies & Drug Stores 9.3.2. Online Channels 9.3.3. Supermarkets & Hypermarkets 9.3.4. Others 9.4. Market Attractiveness Analysis, by Distribution Channel 10. Global Medical Foods Market Analysis and Forecast, by Region 10.1. Key Findings 10.2. Market Value Forecast, by Region 10.2.1. North America 10.2.2. Europe 10.2.3. Asia Pacific 10.2.4. Latin America 10.2.5. Middle East & Africa 10.3. Market Attractiveness Analysis, by Region 11. North America Medical Foods Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Market Value Forecast, by Product Type, 2017–2031 11.2.1. Pills 11.2.2. Powder 11.2.3. Liquid 11.2.4. Others 11.3. Market Value Forecast, by Disease Type, 2017–2031 11.3.1. Orphan Disease 11.3.1.1. Duchenne Muscular Dystrophy (DMD) 11.3.1.2. Sickle Cell Anemia 11.3.1.3. Hemophilia 11.3.1.4. Others 11.3.2. Cancer 11.3.3. Neurological & Psychological Disorders 11.3.4. Metabolic Disorders 11.3.5. Pain Management 11.3.6. Gastrointestinal Disorders 11.3.7. Ophthalmology 11.3.8. Diabetes 11.3.9. Phenylketonuria (PKU) 11.3.10. Epilepsy 11.4. Market Value Forecast, by Route of Administration, 2017–2031 11.4.1. Oral 11.4.2. Enteral 11.5. Market Value Forecast, by Distribution Channel, 2017–2031 11.5.1. Pharmacies & Drug Stores 11.5.2. Online Channels 11.5.3. Supermarkets & Hypermarkets 11.5.4. Others 11.6. Market Value Forecast, by Country, 2017–2031 11.6.1. U.S. 11.6.2. Canada 11.7. Market Attractiveness Analysis 11.7.1. By Product 11.7.2. By Disease Type 11.7.3. By Route of Administration 11.7.4. By Distribution Channel 11.7.5. By Country 12. Europe Medical Foods Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.2. Market Value Forecast, by Product Type, 2017–2031 12.2.1. Pills 12.2.2. Powder 12.2.3. Liquid 12.2.4. Others 12.3. Market Value Forecast, by Disease Type, 2017–2031 12.3.1. Orphan Disease 12.3.1.1. Duchenne Muscular Dystrophy (DMD) 12.3.1.2. Sickle Cell Anemia 12.3.1.3. Hemophilia 12.3.1.4. Others 12.3.2. Cancer 12.3.3. Neurological & Psychological Disorders 12.3.4. Metabolic Disorders 12.3.5. Pain Management 12.3.6. Gastrointestinal Disorders 12.3.7. Ophthalmology 12.3.8. Diabetes 12.3.9. Phenylketonuria (PKU) 12.3.10. Epilepsy 12.4. Market Value Forecast, by Route of Administration, 2017–2031 12.4.1. Oral 12.4.2. Enteral 12.5. Market Value Forecast, by Distribution Channel, 2017–2031 12.5.1. Pharmacies & Drug Stores 12.5.2. Online Channels 12.5.3. Supermarkets & Hypermarkets 12.5.4. Others 12.6. Market Value Forecast, by Country/Sub-region, 2017–2031 12.6.1. Germany 12.6.2. U.K. 12.6.3. France 12.6.4. Spain 12.6.5. Italy 12.6.6. Rest of Europe 12.7. Market Attractiveness Analysis 12.7.1. by Product Type 12.7.2. By Disease Type 12.7.3. By Route of Administration 12.7.4. By Distribution Channel 12.7.5. By Country/Sub-region 13. Asia Pacific Medical Foods Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.2. Market Value Forecast, by Product Type, 2017–2031 13.2.1. Pills 13.2.2. Powder 13.2.3. Liquid 13.2.4. Others 13.3. Market Value Forecast, by Disease Type, 2017–2031 13.3.1. Orphan Disease 13.3.1.1. Duchenne Muscular Dystrophy (DMD) 13.3.1.2. Sickle Cell Anemia 13.3.1.3. Hemophilia 13.3.1.4. Others 13.3.2. Cancer 13.3.3. Neurological & Psychological Disorders 13.3.4. Metabolic Disorders 13.3.5. Pain Management 13.3.6. Gastrointestinal Disorders 13.3.7. Ophthalmology 13.3.8. Diabetes 13.3.9. Phenylketonuria (PKU) 13.3.10. Epilepsy 13.4. Market Value Forecast, by Route of Administration, 2017–2031 13.4.1. Oral 13.4.2. Enteral 13.5. Market Value Forecast, by Distribution Channel, 2017–2031 13.5.1. Pharmacies & Drug Stores 13.5.2. Online Channels 13.5.3. Supermarkets & Hypermarkets 13.5.4. Others 13.6. Market Value Forecast, by Country/Sub-region, 2017–2031 13.6.1. China 13.6.2. Japan 13.6.3. India 13.6.4. Australia & New Zealand 13.6.5. Rest of Asia Pacific 13.7. Market Attractiveness Analysis 13.7.1. by Product Type 13.7.2. By Disease Type 13.7.3. By Route of Administration 13.7.4. By Distribution Channel 13.7.5. By Country/Sub-region 14. Latin America Medical Foods Market Analysis and Forecast 14.1. Introduction 14.1.1. Key Findings 14.2. Market Value Forecast, by Product Type, 2017–2031 14.2.1. Pills 14.2.2. Powder 14.2.3. Liquid 14.2.4. Others 14.3. Market Value Forecast, by Disease Type, 2017–2031 14.3.1. Orphan Disease 14.3.1.1. Duchenne Muscular Dystrophy (DMD) 14.3.1.2. Sickle Cell Anemia 14.3.1.3. Hemophilia 14.3.1.4. Others 14.3.2. Cancer 14.3.3. Neurological & Psychological Disorders 14.3.4. Metabolic Disorders 14.3.5. Pain Management 14.3.6. Gastrointestinal Disorders 14.3.7. Ophthalmology 14.3.8. Diabetes 14.3.9. Phenylketonuria (PKU) 14.3.10. Epilepsy 14.4. Market Value Forecast, by Route of Administration, 2017–2031 14.4.1. Oral 14.4.2. Enteral 14.5. Market Value Forecast, by Distribution Channel, 2017–2031 14.5.1. Pharmacies & Drug Stores 14.5.2. Online Channels 14.5.3. Supermarkets & Hypermarkets 14.5.4. Others 14.6. Market Value Forecast, by Country/Sub-region, 2017–2031 14.6.1. Brazil 14.6.2. Mexico 14.6.3. Rest of Latin America 14.7. Market Attractiveness Analysis 14.7.1. by Product Type 14.7.2. By Disease Type 14.7.3. By Route of Administration 14.7.4. By Distribution Channel 14.7.5. By Country/Sub-region 15. Middle East & Africa Medical Foods Market Analysis and Forecast 15.1. Introduction 15.1.1. Key Findings 15.2. Market Value Forecast, by Product Type, 2017–2031 15.2.1. Pills 15.2.2. Powder 15.2.3. Liquid 15.2.4. Others 15.3. Market Value Forecast, by Disease Type, 2017–2031 15.3.1. Orphan Disease 15.3.1.1. Duchenne Muscular Dystrophy (DMD) 15.3.1.2. Sickle Cell Anemia 15.3.1.3. Hemophilia 15.3.1.4. Others 15.3.2. Cancer 15.3.3. Neurological & Psychological Disorders 15.3.4. Metabolic Disorders 15.3.5. Pain Management 15.3.6. Gastrointestinal Disorders 15.3.7. Ophthalmology 15.3.8. Diabetes 15.3.9. Phenylketonuria (PKU) 15.3.10. Epilepsy 15.4. Market Value Forecast, by Route of Administration, 2017–2031 15.4.1. Oral 15.4.2. Enteral 15.5. Market Value Forecast, by Distribution Channel, 2017–2031 15.5.1. Pharmacies & Drug Stores 15.5.2. Online Channels 15.5.3. Supermarkets & Hypermarkets 15.5.4. Others 15.6. Market Value Forecast, by Country/Sub-region, 2017–2031 15.6.1. GCC Countries 15.6.2. South Africa 15.6.3. Rest of Middle East & Africa 15.7. Market Attractiveness Analysis 15.7.1. by Product Type 15.7.2. By Disease Type 15.7.3. By Route of Administration 15.7.4. By Distribution Channel 15.7.5. By Country/Sub-region 16. Competition Landscape 16.1. Market Player - Competition Matrix (by tier and size of companies) 16.2. Competitive Business Strategies 16.3. Company Profiles 16.3.1. Nutricia (Danone) 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.1.2. Product Portfolio 16.3.1.3. Financial Overview 16.3.1.4. SWOT Analysis 16.3.1.5. Strategic Overview 16.3.2. Nestlé S.A. 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.2.2. Product Portfolio 16.3.2.3. Financial Overview 16.3.2.4. SWOT Analysis 16.3.2.5. Strategic Overview 16.3.3. Abbott Laboratories 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.3.2. Product Portfolio 16.3.3.3. Financial Overview 16.3.3.4. SWOT Analysis 16.3.3.5. Strategic Overview 16.3.4. Mead Johnson Nutrition 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.4.2. Product Portfolio 16.3.4.3. Financial Overview 16.3.4.4. SWOT Analysis 16.3.4.5. Strategic Overview 16.3.5. Fresenius Kabi 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.5.2. Product Portfolio 16.3.5.3. Financial Overview 16.3.5.4. SWOT Analysis 16.3.5.5. Strategic Overview 16.3.6. Friso 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.6.2. Product Portfolio 16.3.6.3. Financial Overview 16.3.6.4. SWOT Analysis 16.3.6.5. Strategic Overview 16.3.7. Morinaga Milk Industry 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.7.2. Product Portfolio 16.3.7.3. Financial Overview 16.3.7.4. SWOT Analysis 16.3.7.5. Strategic Overview 16.3.8. Primus Pharmaceuticals, Inc. 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.8.2. Product Portfolio 16.3.8.3. Financial Overview 16.3.8.4. SWOT Analysis 16.3.8.5. Strategic Overview 16.3.9. Targeted Medical Pharma, Inc. 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.9.2. Product Portfolio 16.3.9.3. Financial Overview 16.3.9.4. SWOT Analysis 16.3.9.5. Strategic Overview 16.3.10. Medtrition, Inc. 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.10.2. Product Portfolio 16.3.10.3. Financial Overview 16.3.10.4. SWOT Analysis 16.3.10.5. Strategic Overview List of Tables/GraphsList of TablesTable 01: Global Medical Foods Market Value (US$ Mn) Forecast, by Product Type, 2017–2031 Table 02: Global Medical Foods Market Value (US$ Mn) Forecast, by Disease Type, 2017–2031 Table 03: Global Medical Foods Market Value (US$ Mn) Forecast, by Orphan Disease, 2017–2031 Table 04: Global Medical Foods Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031 Table 05: Global Medical Foods Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031 Table 06: Global Medical Foods Market Value (US$ Mn) Forecast, by Country, 2017–2031 Table 07: Europe Medical Foods Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031 Table 08: Europe Medical Foods Market Value (US$ Mn) Forecast, by Product Type, 2017–2031 Table 09: Europe Medical Foods Market Value (US$ Mn) Forecast, by Disease Type, 2017‒2031 Table 10: Europe Medical Foods Market Value (US$ Mn) Forecast, by Orphan Disease, 2017‒2031 Table 11: Europe Medical Foods Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031 Table 12: Europe Medical Foods Value (US$ Mn) Forecast, by Distribution Channel, 2017‒2031 Table 13: North America Medical Foods Market Value (US$ Mn) Forecast, by Product Type, 2017–2031 Table 14: North America Medical Foods Market Value (US$ Mn) Forecast, by Disease Type, 2017‒2031 Table 15: North America Medical Foods Market Value (US$ Mn) Forecast, by Orphan Disease, 2017‒2031 Table 16: North America Medical Foods Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031 Table 17: North America Medical Foods Value (US$ Mn) Forecast, by Distribution Channel, 2017‒2031 Table 18: Asia Pacific Medical Foods Market Value (US$ Mn) Forecast, by Product Type, 2017–2031 Table 19: Asia Pacific Medical Foods Market Value (US$ Mn) Forecast, by Disease Type, 2017‒2031 Table 20: Asia Pacific Medical Foods Market Value (US$ Mn) Forecast, by Orphan Disease, 2017‒2031 Table 21: Asia Pacific Medical Foods Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031 Table 22: Asia Pacific Medical Foods Value (US$ Mn) Forecast, by Distribution Channel, 2017‒2031 Table 23: Latin America Medical Foods Market Value (US$ Mn) Forecast, by Product Type, 2017–2031 Table 24: Latin America Medical Foods Market Value (US$ Mn) Forecast, by Disease Type, 2017‒2031 Table 25: Latin America Medical Foods Market Value (US$ Mn) Forecast, by Orphan Disease, 2017‒2031 Table 26: Latin America Medical Foods Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031 Table 27: Latin America Medical Foods Value (US$ Mn) Forecast, by Distribution Channel, 2017‒2031 Table 28: Middle East and Africa Medical Foods Market Value (US$ Mn) Forecast, by Product Type, 2017–2031 Table 29: Middle East and Africa Medical Foods Market Value (US$ Mn) Forecast, by Disease Type, 2017‒2031 Table 30: Middle East and Africa Medical Foods Market Value (US$ Mn) Forecast, by Orphan Disease, 2017‒2031 Table 31: Middle East and Africa Medical Foods Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031 Table 32: Middle East and Africa Medical Foods Value (US$ Mn) Forecast, by Distribution Channel, 2017‒2031
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(その他)の最新刊レポート
Transparency Market Research 社の最新刊レポート
本レポートと同じKEY WORD(administration)の最新刊レポート
よくあるご質問Transparency Market Research社はどのような調査会社ですか?トレンスペアレンシーマーケットリサーチ(Transparency Market Research /TMR)は市場参入やホワイトスペースの特定、新商品や新サービスの立ち上げ、戦略的M&Aなどの実現のた... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/09/17 10:30 141.77 円 158.05 円 189.84 円 |